# US 2014/0154227 A1 · Cell populations having immunoregulatory activity, method for isolation and uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154227 A1
- Document ID: US20140154227A1
- Status: Published application
- Kind: A1
- Application number: 14/004,004
- Filed: 2012-03-12
- Published: 2014-06-05
- Earliest claimed: 2011-03-11
- Inventors: Javier Garcia Casado; Raquel Tarazona Lafarge; Olga De La Rosa
- Web page: https://patentgrep.com/patent/US20140154227A1

## CPC

- C12N 5/0667: {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
- A61K 40/10: characterised by the cell type used
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- C12N 5/0663: {Bone marrow mesenchymal stem cells (BM-MSC)}
- A61K 2035/122: {for inducing tolerance or supression of immune responses}
- C12N 2502/1358: Bone marrow mesenchymal stem cells (BM-MSC)
- C12N 2502/1382: Adipose-derived stem cells [ADSC], adipose stromal stem cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a population of mesenchymal cells that do not express the cell surface markers CD112 and/or CD155 for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.

## Claims

### Claim at position 1

-11. (canceled)

### Claim 12

An isolated mesenchymal stem cell population characterised in that the cells of said population do not express CD112 and/or CD155.

### Claim 13 (depends on 12)

The cell population according to claim 12, characterised in that it is positive for at least one and preferably all the following cell surface markers: CD11b, CD11c, CD14, CD45, HLAII, CD31, CD34, CD45, 1B10 (αFSP), FceR1α and CD133.

### Claim 14 (depends on 12)

A method for isolating a cell population according to claim 12 comprising the steps of:
(i) preparing a cell suspension from a sample of adipose tissue;
(ii) recovering the cells from said cell suspension;
(iii) incubating said cells in a suitable cell culture medium on a solid surface under conditions which allow cells to adhere to the solid surface and proliferate;
(iv) removing non-adhered cells;
(v) selecting the cells which after being passaged at least twice in such medium remain adhered to said solid surface;
(vi) determining the presence or absence of determining the presence or absence of markers CD112 and/or CD155 in individual cells or subpopulations; and
(vii) selecting the cells or subpopulations negative for the markers CD112 and/or CD155

### Claim 15 (depends on 12)

A method for the preparation of a T-reg cell population which comprises:
(a) contacting a cell population according to claim 12 with peripheral blood leukocytes, and
(b) selecting the T-reg cell population.

### Claim 16 (depends on 15)

An isolated T-reg cell population obtainable according to the method of claim 15.

### Claim 17 (depends on 12)

A pharmaceutical composition comprising a cell population according to claim 12 and a pharmaceutically acceptable carrier.

### Claim 18 (depends on 12)

A method for preventing, treating, or ameliorating one or more symptoms associated with autoimmune diseases, inflammatory disorders, or immunologically mediated diseases, in a subject suffering from said disorders or diseases, which comprises administering to said subject in need of such treatment of a prophylactically or therapeutically effective amount of a cell population according to claim 12.

### Claim 19 (depends on 18)

The method according to claim 18, wherein said inflammatory disease is a chronic inflammatory disease.

### Claim 20 (depends on 19)

Method according to claim 19, wherein said chronic inflammatory disease is selected from the group consisting of Inflammatory Bowel Disease (IBD) and Rheumatoid Arthritis (RA).

### Claim 21 (depends on 12)

A method for selection of cells according to claim 12 comprising the following steps:
i) providing a population of mesenchymal stem cells comprising cells having the capacity to be differentiated into at least two cell lineages;
ii) determining the presence or absence of markers CD112 and/or CD155 in cells or subpopulations of said population of adipose derived cells; and
iii) selecting the cells or subpopulations negative for the markers CD112 and/or CD155.

### Claim 22 (depends on 16)

A method for preventing, treating, or ameliorating one or more symptoms associated with autoimmune diseases, inflammatory disorders, or immunologically mediated diseases, in a subject suffering from said disorders or diseases, which comprises administering to said subject in need of such treatment of a prophylactically or therapeutically effective amount of a T-reg cell population according to claim 16.

### Claim 23 (depends on 22)

The method according to claim 22, wherein said inflammatory disease is a chronic inflammatory disease.

### Claim 24 (depends on 23)

The method according to claim 23, wherein said chronic inflammatory disease is selected from the group consisting of Inflammatory Bowel Disease (IBD) and Rheumatoid Arthritis (RA).

### Claim 25 (depends on 17)

A method for preventing, treating, or ameliorating one or more symptoms associated with autoimmune diseases, inflammatory disorders, or immunologically mediated diseases, in a subject suffering from said disorders or diseases, which comprises administering to said subject in need of such treatment of a prophylactically or therapeutically effective amount of a pharmaceutical cell composition according to claim 17.

### Claim 26 (depends on 25)

The method according to claim 25, wherein said inflammatory disease is a chronic inflammatory disease.

### Claim 27 (depends on 26)

Method according to claim 26, wherein said chronic inflammatory disease is selected from the group consisting of Inflammatory Bowel Disease (IBD) and Rheumatoid Arthritis (RA).
